Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy (HAM). In asymptomatic carriers and HAM patients, HTLV-1 infection leads to a vigorous cytotoxic T-cell (CTL) response mainly directed to the regulatory Tax protein. In contrast, initial studies showed that anti-HTLV-1 CTL activities were not reproductively detected in ATLL patients, neither ex vivo, nor after in vitro restimulation. To better understand this discrepancy, we explored the anti-HTLV-1 CD8 þ T-cell response of eight ATLL patients by using in vitro restimulated or freshly isolated CD8 þ T cells. In all the ATLL patients, we found that mitogenic activation allowed the induction of CD8 þ T cells able to lyse autologous HTLV-1-infected cells and/or to produce IFNc in response to Tax peptides. In contrast, only a minority of the patients possessed CD8 þ cells able to respond ex vivo to the same epitopes. These findings indicate that although a restimulatable anti-HTLV-1 CTL activity persists during ATLL, the specific ex vivo response is not constantly maintained. This provides definitive evidence that the CD8 þ T-cell response to HTLV-1 is affected by ATLL development and reveals that a major defect concerns the generation and/or the functionality of CD8 þ effectors.
Introduction
Human T-cell leukemia virus type I (HTLV-1) is a retrovirus responsible for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and for an aggressive proliferation of CD4 þ T lymphocytes known as adult T-cell leukemia/ lymphoma (ATLL). ATLL exists as different clinical forms, including acute, smoldering and chronic leukemia, and T-cell lymphoma. 1 The appearance of ATLL seems to be favored by early transmission from mother to child, 2 whereas HAM/TSP is rather associated to repeated contaminations 3 and/or contamination with high doses of virus. 4 Consequently, HAM/TSP is characterized by an increase of the proviral loads 5 and of the frequency of in vivo activated anti-HTLV-1 cytotoxic T lymphocytes (CTLs), as compared to asymptomatic carriers. 6, 7 Despite this pathogenic role assumed in HAM/TSP patients, the anti-HTLV-1 cytotoxic response seems, however, to be rather protective in asymptomatic carriers since some MHC-I alleles are significantly associated with reduced proviral loads as well as with a lower risk of HAM/TSP. 8 Numerous studies have allowed the characterization of CTLs to HTLV-1 in HAM/TSP patients and asymptomatic carriers. In both groups, specific CD8 þ T cells are mainly directed to the regulatory Tax protein, 9 in which multiple epitopes are simultaneously recognized. 10, 11 This population is composed of precursor and/or memory cells whose activity can be restimulated in vitro via polyclonal 12 or antigen-specific (autologous HTLV-1-infected CD4 þ T cells) activation, 13 and of effectors, which respond directly ex vivo. 7, 10, 14 The presence of the former population reflects the constant expansion and differentiation of CD8 þ T-cell precursor or memory cells in response to chronic Tax production in vivo. 15, 16 The status and impact of the anti-HTLV-1 CTL response in ATLL patients are less documented. One initial study reported the absence of both ex vivo and restimulatable anti-Tax activities in PBMC from an ATLL patient. 17 In other studies, anti-HTLV-1 CTL activities were detected when multiple in vitro antigenic restimulations of PBMC were performed, but only in some patients. 13, 18 This has provided the notion that ATLL patients are deficient with regard to the anti-HTLV-1 CTL response, which has been proposed to represent a key event for disease development. 19 More recently, however, new evidence has emerged suggesting that a potent CD8 þ T-cell response to HTLV-1 exists in ATLL patients. This includes the report of peculiar MHC-I alleles more represented in ATLL patients, 20 and the description in ATLL cells of Tax genes bearing escape mutations in immunodominant CTL epitopes. 21 Consistently with these findings, we previously characterized CTLs directed to various HTLV-1 epitopes in a patient with acute ATLL.
14 To gain further insight on the status of the anti-HTLV-1 CTL response in ATLL patients, we extended our previous investigation to eight new patients with different clinical subtypes of the disease. We examined the ability of in vitro restimulated CD8 þ T to lyse autologous HTLV-1-infected cells, analyzed the response to Tax in these cultures and finally, investigated whether the ex vivo response to Tax is maintained in ATLL patients.
Materials and methods

Subjects
After informed consent, HTLV-1-infected patients with ATLL (ATLL1-ATLL8) were recruited in the hematology departments of Hô pital Necker and Hô pital Saint Louis (Paris, France). The diagnosis and clinical subtype of ATLL was made according to the Shimoyama's criteria. 1 Blood samples of all patients but ATLL3 and ATLL4 were obtained before treatment. ATLL3 and ATLL4 were, respectively, under treatments by CHOP/MTX or lamivudine plus IFNa. Biological and immunological characteristics of the ATLL patients are detailed in Table 1 .
Patient HAM1 (HLA-A n 02) with HAM/TSP was recruited at Hô pital Pitié-Salpétrière (Paris, France), asymptomatic carriers AC1, AC2 (HLA-A n 02) and AC3 (HLA-B n 35) at the Transfusion center of Pointe-à-Pitre (French West Indies) and carrier AC4 was from Hô pital Saint Louis (Paris). PBMCs from the noninfected control donor (NI) were kindly provided by Hélène Teisserenc (Hô pital Saint Louis, Paris).
Cell lines and peptides
Polyclonal CD8 þ T-cell lines (CD8 þ ) were produced from CD8 þ T lymphocytes purified from unfrozen PBMCs by positive selection using anti-CD8-coated magnetic microbeads (MACS reagent, Miltenyi Biotec, France) or in some cases, from CD4À T lymphocytes negatively selected using anti-CD4-coated magnetic microbeads. CD8 þ and CD4À T cells were then stimulated with 1 mg/ml phytohemagglutin (PHA-M, SIGMA, France) and grown in RPMI medium containing 100 U/ml interleukin 2 (Roussel Uclaf, France).
14 HTLV-1-chronically-infected (HCI) CD4 þ T-cell lines (named HCI-donor code) were established from long-term culture of CD8À PBMC stimulated with 1 mg/ml PHA-M and cultivated with 100 U/ml IL-2. HTLV-1 expression was monitored by indirect immunofluorescence and Western blot using a monoclonal antibody from the anti-Tax hybridoma 168-A51 (NIH AIDS Research and Reagent Program).
Tax peptides (15 mer) corresponding to the previously characterized 10 All the peptide solutions were previously used and found to be recognized by CD8 þ T cells from some HTLV-1-infected individuals according to their MHC-I haplotypes.
Chromium release cytotoxic assay
Cytotoxic activity was tested against HCI CD8À cells or against PHA-stimulated CD8 þ T cells. Target cells were incubated with 100 mCi chromium 51 (NEN, France) in 100 ml culture medium for 1 h at 371C, washed twice with culture medium and plated in duplicates in a 96-well (round bottom) culture plate (2000 cells per well in 100 ml of culture medium). CD8 þ T cells were then added in 100 ml culture medium at an effector to target ratio of 40:1 and the plates were incubated at 371C for 5 h. Aliquots (100 ml) of supernatant were collected and the radioactivity was counted in a gamma counter (Amersham Pharmacia Biotech, France).
ELISPOT assay
Nitrocellulose plates (96-well, Millipore) were coated with 50 ml monoclonal anti-human IFNg antibody (Genzyme, 2 mg/ml) in carbonate buffer (15 mM NaHCO 3 , 33 mM Na 2 CO 3 , pH 9.5) for 16 h at 41C. The wells were washed twice with culture medium and incubated with 200 ml of the same medium for 2 h at 371C. Freshly isolated CD8 þ T cells or purified CD8 þ or CD4À T lymphocytes cultivated 10-15 days following PHA stimulation were first incubated in culture medium overnight to allow antibody detachment. They were then plated in triplicates at 5 Â 10 4 /well and peptides (5 mM) were added in a total volume of 200 ml. A total of 500 cells were also activated with phorbol ester (PMA, 50 ng/ml, SIGMA, France) and ionomycin (500 ng/ ml, SIGMA, France), as a positive control of exogenous stimulation. The plates were incubated for 24 h at 371C, washed six times with PBS containing 0.05% Tween 20 (PBS-Tween). Polyclonal rabbit anti-human IFNg (Genzyme, 100 ml of a 1:250 dilution in PBS-Tween containing 1% BSA) was added to each well and the plates were incubated at 41C overnight. They were washed six times with PBS-Tween, and biotin-conjugated-antirabbit F(ab 0 )2 fragment (Roche, 100 ml of a 1:500 dilution in PBS-Tween-BSA) was added to each well. The plates were incubated for 1 h at 371C, washed six times, and incubated with alkaline phosphatase-conjugated-streptavidin (SIGMA, 100 ml of a 1:6000 dilution in PBS-Tween-BSA) for 1 h at 371C. Plates were washed six times, and 100 ml alkaline phosphatase substrate (Biorad, France) was added to each well and the plates incubated for 1-2 h. Lastly, the plates were washed in water, air-dried and the colored spots were counted under a stereomicroscope.
Results
The absolute number of CD8 þ T cells is not massively decreased in ATLL patients
Since previous studies have reported that the CTL response to HTLV-1 in PBMC was barely detectable in ATLL patients, 13 ,17,18 Normal values are between 400 to 800 CD8+ T cells/ml of blood. ND: not determined.
CTLs to Tax in adult -T-cell leukemia/lymphoma patients B Arnulf et al we first investigated whether such a phenomenon could just reflect a massive decrease in the number of circulating CD8 þ T cells. Blood samples were obtained from five ATLL patients, with acute (ATTL1, ATLL3, ATLL5) or chronic (ATLL4) leukemia or cutaneous T-cell lymphoma (ATLL2) ( Table 1) , and either before (ATLL1, ATLL2, and ATLL5) or during treatment (ATLL3, ATLL4)(see Materials and methods). T-lymphocyte counts at the date of sampling showed that the percentage of CD8 þ T cells was strongly decreased in the patients, especially in those with acute form of ATLL (ATLL1, ATLL5). However, when reported to the total lymphocytes count, the absolute number of CD8 þ T cells was either close to normal values (ATLL2, ATLL3, ATLL5) or decreased by a factor 2 (ATLL1) or 3 (ATLL4). This shows that a significant amount of circulating CD8 þ T cells was still present and therefore that, at least in these five patients, a potential defect in the CTL response to HTLV-1 would not be explained by an absence of CD8 þ T lymphocytes. However, to avoid dilution of these cells by HTLV-1-transformed CD4 þ T cells, which could render difficult the detection of the CTL activity, we decided to conduct the following experiments using purified CD8 þ T cells.
PHA-stimulated CD8 þ T cells from all the ATLL patients tested recognized autologous HTLV-1-infected T cells
It has been previously shown that PHA stimulation of CD8 þ T cells from asymptomatic carriers and HAM/TSP patients allows the reactivation of CTL that strongly recognized multiple epitopes of Tax. 10, 11 Such cells with long-term proliferative capacity are believed to mainly represent CD8 þ precursors or memory T lymphocytes. 23 We wondered whether an antiviral CTL activity could be similarly reactivated from CD8 þ T cells of ATLL patients. PHA-stimulated purified CD8 þ T cells were cultivated with IL-2 for at least 2 weeks and then their ability to lyse autologous infected cells was carried out using the chromiun release assay (Figure 1a) . CTL line from patient HAM1 used as a positive control was, as expected, able to lyse its autologous HTLV-1-infected T-cell line (Figure 1a) . A similar cytotoxicity to autologous infected cells was also found in CTL lines established from patients ATLL 1, ATTL3, ATLL4 and ATLL5. No autologous infected cells could be obtained for patient ATLL2, but since its CD8 þ T cells were able to lyse HCI-ATLL4 and HCI-ATLL1 (cross lysis, see below), we concluded that CTL to HTLV-1 were also present in this patient. No lysis was found when CTL lines were used both as target and effector cells (Figure 1b) , indicating that the restimulated CD8 þ T cells did not respond to self epitopes. Consistent with CTL activity, the cytotoxicity was inhibited by adding anti-MHC-I but not anti-MHC-II antibodies (not shown). MHC-I restriction was also evidenced by the ability of CD8 þ Tcell lines to kill infected target cells sharing the expression of some MHC-I molecules (see the cross lysis between ATLL5 and HAM1, ATLL4 and ATLL2 and ATLL2 and ATLL1, in Figure 1a ). That CD8 þ T cells from patient ATLL3 did not recognize HCI-HAM1 and HCI-ATLL5 was probably due to an A n 02 subtype difference, since HAM1 and ATLL5 are HLA-A n 0201, whereas patient ATLL3 is HLA-A n 0202 (Table 1) . Collectively, these results demonstrate that, regardless of MHC-I haplotype, clinical subtypes and treatment, a conventional MHC-I-restricted CTL activity to HTLV-1-producing cells can be reinduced from circulating CD8 þ T cells of ATLL patients.
CTL lines from
The regulatory Tax protein is the immunodominant antigen for CTLs in asymptomatic carriers and HAM/TSP patients. 9, 24 Therefore, we investigated whether this protein was also the target of restimulated CD8 þ T cells obtained from ATLL patients. This was addressed using the IFNg ELISPOT assay in order to obtain both a qualitative and quantitative estimation of the anti-Tax response.
14 Experiments were performed with samples from HLA-A n 02 and HLA-B n 35 ATLL patients and asymptomatic carriers, since several potent Tax epitopes presented in association with these molecules have been previously characterized.
10,11 CD8 þ T cells from CTL lines were stimulated with HLA-A n 02-restricted (Tax 11 (Tables 2 and 3 ). Based on a previous study, 14 a cutoff of 5 spots/5 Â 10 4 CD8 þ T cells (corresponding to a frequency of 1/10 000) was used to identify positive response to peptides.
All CD8 þ T-cell lines gave similar responses to mitogenic stimulation showing that their viability and ability to secrete IFNg were comparable (Tables 2 and 3 The production of IFNg was also detected in CD8 þ T-cell lines from patients ATLL2 and ATLL4 and carrier AC3 following stimulation with the HLA-B n 35-restricted Tax 131-145 epitope (18, 50 and 100 spots/5 Â 10 4 CD8 þ T cells, respectively) ( Table 3 ). The frequencies of responding CD8 þ T cells were comparable between ATLL4 and AC3 (1/1000 vs 1/500), whereas it was lower in patient ATLL2 (1/2.800). CD8 þ Tcell lines from patients ATLL4 and ATLL2 did not recognize the Tax 141-155 and the Tax 211-225 peptides, whereas these peptides were efficiently recognized by CD8 þ T cells from AC3.
These results first indicate that the Tax protein is also a potent target of the CD8 þ T-cell response found during ATLL. They also reveal that the frequency of restimulated CD8 þ T cells directed to certain Tax epitopes can be comparable between some ATLL patients and asymptomatic carriers, showing that a reinducible anti-Tax repertoire is maintained during ATLL. That some but not all known Tax epitopes were recognized by the CD8 þ T-cell lines from the ATLL patients tested suggested, however, that qualitative alterations of the anti-Tax response might appeared as a consequence of disease development.
An ex vivo response to tax is not reproducibly detected in CD8 þ T cells from ATLL patients
In asymptomatic carriers and individuals with inflammatory diseases, precursor and/or memory cells constantly differentiate in response to viral stimulation into CD8 þ effectors whose activities can be directly detected ex vivo. 7, 10, 14 We then investigated whether an ex vivo response to Tax could also be found in ATLL patients. This was first done using purified CD8 þ T cells from the three HLA-A n 02 or B n 35 ATLL patients in whom a reinducible response to Tax was found (ATLL2, ATLL4, ATLL5). CD8 þ T cells were stimulated with cognate Tax peptides just after the anti-CD8 magnetic sorting, and production of IFNg was measured by ELISPOT (Table 4) .
The mitogenic stimulation of uncultivated CD8 þ T lymphocytes induced a large IFNg production, demonstrating that the cells were viable and functional (Table 4 ). In the HLA-B n 35 ATLL4 patient, a significant ex vivo response to the Tax 131-145 epitope and a lower response to the Tax 301-315 peptide was detected (70 and 18 spots/5 Â 10 4 CD8 þ T cells, respectively), whereas two others known HLA-B n 35-restricted Tax epitopes were not recognized. Only a very low ex vivo response to the Tax 131-145 peptide was observed in HLA-B n 35 patient ATLL2 (11 spots spots/5 Â 10 4 CD8 þ T cells), and no response to four Tax peptides was detected in HLA-A n 02 patient ATLL5. The above results suggested that in contrast to asymptomatic carriers and HAM/TSP patients, an ex vivo response to Tax was not reproducibly maintained in ATLL patients. To confirm these findings, we investigated the ex vivo and reinducible CD8 þ Tcell responses to Tax in three additional ATLL patients who suffered from a T-cell lymphoma (ATLL6), or an acute (ATLL7) or chronic (ATLL8) leukemia. To rule out cell toxicity due to intensive therapy, blood samples were obtained just before the beginning of treatment. Moreover, to ensure that an absence of ex vivo response would not be the result of an anergic or Table 2 Response to Tax epitopes of CTL lines from two HLA-A*02 asymptomatic carriers and one HLA-A*02 ATLL patient CTLs to Tax in adult -T-cell leukemia/lymphoma patients B Arnulf et al apoptotic effect of the CD8 selection, a CD4-negative selection was performed on PBMC, and IFNg production was assessed on the recovered CD4À T cells. Finally, stimulation was not performed with single epitope but with three pools of 10 peptides, encompassing the entire sequence of the protein (see Material and methods), as previously described. 10, 12 Although a slight decrease of sensitivity was expected with such pool stimulation, this increases the probability that at least one Tax peptide was recognized by CD8 þ T cells. IFNg production of CD4À T cells freshly isolated or cultivated for 14 days following PHA restimulation was measured by the ELISPOT assay for ATLL6, ATLL7 and ATLL8 patients and, as controls, one asymptomatic carrier (AC4) and one HTLV-1 NI donor (Table 5 ).
All the CD4À T-cell populations responded to mitogen, indicating that they were viable and functional (Table 5) . A maximum of 2 spots/10 5 CD4À T cells was measured in cells from the uninfected donor showing that none of the pool Tax peptides induced a nonspecific IFNg production. As expected, an ex vivo response was detected in CD4À T cells from AC4 (pools 1 and 2, 14 and 38 spots/10 5 CD4À T cells, respectively). A quantitatively comparable ex vivo response was found in cells from ATLL6 after stimulation with the three pools of Tax peptides (16, 21 and 38 spots), and these responses were maintained in mitogen-stimulated cell populations kept 14 days in culture (17, 34 and 30 spots). In contrast, no significant ex vivo activity to either pools was found in cells from ATLL7 (À2, À2 and À4 spots) and ATLL8 (2, 4 and 3 spots) even though a significant IFNg production appeared in both cell populations when stimulated and grown in culture for 14 days (ATLL7, pool 1: 20 spots; ATLL8, pools 1-3: 20, 25 and 10 spots). These results confirm that a response to Tax could be constantly reinduced in CD8 þ T cells from ATLL patients following polyclonal stimulation. They also strongly reinforce the notion that, in contrast, the ex vivo activity to Tax is not always maintained following disease development.
Discussion
In both asymptomatic carriers and HAM/TSP patients, HTLV-1 persistent infection is associated to a vigorous CTL response to the Tax protein, including the generation of both memory cells whose activity is reinducible in vitro 11 and effectors that respond directly ex vivo. 7, 10 In this study, we analyzed the CD8 þ T-cell responses to HTLV-1 in eight patients with HTLV-1-associated adult T-cell leukemia/lymphoma. We found that although a reinducible CTL response to HTLV-1 persists regardless of the clinical status of the patients, the persistence of a direct ex vivo response to Tax is not a constant feature. This provides definitive Table 4 Quantification CTLs to Tax in adult -T-cell leukemia/lymphoma patients B Arnulf et al evidence that the CD8 þ T-cell response to HTLV-1 is affected by ATLL development. Previous studies have reported that a specific CTL activity was not reproducibly detected in ATLL patients, even after multiple in vitro restimulations of PBMC. 13, 18 In contrast, using purified CD8 þ T lymphocytes instead of PBMC, we documented a potent reinducible response to HTLV-1 and/or Tax peptides in all the ATLL patient tested. We assume that the previous failure to detect CTL activities in some ATLL patients was due to the initial dilution of CD8 þ T cells by leukemic cells, or alternatively to the production by ATLL cells of inhibitory cytokines such as TGF-b and IL-10. 25, 26 In both asymptomatic carriers and HAM/TSP patients, the CTL response to HTLV-1 is mainly directed to the regulatory Tax protein. 9 We found that restimulated CD8 þ T cells from ATLL patients recognized Tax epitopes previously characterized in the other groups of infected individuals. 10, 11 Moreover, we showed that in two patients with either acute (ATLL5) or chronic (ATLL4) ATLL, the frequency of IFN-g-producing CD8 þ T cells, directed to at least one Tax epitope, was closed to that found in HLAmatched asymptomatic carriers. Regardless of a particular MHC-I molecule expression, comparable amounts of T cells directed to pools of Tax peptides were also found in CTL lines established from three additional ATLL patients, as compared to one asymptomatic carrier. CD8 þ T cells that proliferate in long-term culture correspond mainly to precursor and/or memory cells that differentiated into effectors in response to polyclonal stimulation. 10, 23 Hence, our results indicate that a population of anti-HTLV-1 precursor and/or memory cells is still present during ATLL, whatever may be the clinical subtypes. It seems likely that these cells originate from the pool of CD8 þ precursor and/or memory cells that have been generated during the asymptomatic stage of infection, and that still persists in the organism concomitantly to ATLL development.
We also found that CTL lines from ATLL patients simultaneously recognized at least two epitopes of Tax. However, we noticed that among the four HLA-A n 02-and the three B n 35-restricted peptide tested, only one peptide was strongly recognized by CTL lines from ATLL patients (Tax 151-165 for ATLL5 and Tax 131-145 for ATTL2 and ATLL4), whereas in the same experiments, CTL lines from AC strongly recognized two or more Tax peptides. This suggests that some qualitative alterations exist in the CD8 þ T-cell response of ATLL patients when compared with asymptomatic carriers. However, according to our results (see Figure 1) , this restricted response is still functional since it is sufficient to prompt lysis of autologous infected cells.
In contrast to the reinducible response, we found that the ex vivo CD8 þ T-cell response to Tax was not maintained in all the ATLL patients. Indeed, among six patients tested, only two (ATLL4 and ATLL6) responded ex vivo to at least one Tax epitope. This persistent ex vivo response is interesting since it demonstrates that the differentiation process from precursor/ memory to effector cells can remain efficient during ATLL and, consequently, that Tax can be still chronically produced in this pathological context. It has been recently evidenced that Tax is synthesized in circulating CD4 þ and, to a lesser extent, CD8 þ T lymphocytes, in both HAM/TSP patients and asymptomatic carriers. 15, 16 We postulate that this production is maintained in ATLL4 and ATLL6, which explains the constant generation of CD8 þ effectors. However, that no ex vivo response was detected in the other patients tested strongly suggests that the in vivo process of CD8 þ T-cell differentiation and/or the functionality of the primed CD8 þ are generally deficient during ATLL. Since we obtained only a limited amount of blood from each ATLL patient, we had to focus our study on the HTLV-1-specific activity. It remains therefore to establish whether the defect observed in the majority of ATLL patients is restricted to the anti-HTLV-1 CD8 þ T-cell response of whether it constitutes a broader perturbation of the cellular immunity.
The defect of ex vivo response we documented can be directly attributed neither to the patients' treatments, since experiments were mainly performed with samples obtained before therapy, nor to the MHC-I haplotype, since the tested patients expressed different MHC-I molecules. That no ex vivo response was found in two patients with acute leukemia, but not in a patient with a chronic form suggests that the CD8 þ T cell priming defect might be linked to the degree of expansion of ATLL cells in vivo. Indeed, since ATLL cells have been shown to constitutively produce cytokines with immunosuppressive properties such as TGF-b, 26 IL-10, 25 and VEGF, 27 their massive proliferation in vivo could strongly impair the processes of CD8 þ T-cell proliferation and differentiation. Reduced priming of CD8 þ T cells could also be related to mechanism of immune escape developed in ATLL cells such as extinction of Tax expression [28] [29] [30] and/or decreased recognition of Tax epitopes due to downregulation of MHC-I expression 31 or mutations into immunodominant Tax epitopes. 21 In conclusion, we demonstrated that the anti-HTLV-1 CD8 þ T-cell response found in ATLL patients differs from that of other HTLV-1-infected individuals because CD8 þ effectors are not generated or are not functional. However, a still functional antiviral repertoire is maintained regardless of the clinical forms of ATLL, since CTLs able to lyse autologous-infected cells can be reproducibly reinduced in all patients. Recent studies in a rat animal model have shown that adoptive transfer of specific CD8 þ T cells allows the clearance of HTLV-1-transformed CD4 þ T cells. 32 These findings and our results could constitute the rationale for the set up of an immunotherapy of HTLV-1-associated hematological diseases based on the reactivation of the anti-HTLV-1 repertoire still present in ATLL patients.
